Associated Papers
Prime editing-installed suppressor tRNAs for disease-agnostic genome editing.
Pierce SE et al.
Nature, 2025
Primary exploration of cell-free DNA in the plasma of patients with parathyroid neoplasms using next-generation sequencing.
Zheng Q et al.
Cancer Cell International, 2025
Molecular Genetic Aspects of Sporadic Multiglandular Primary Hyperparathyroidism.
Včelák J et al.
Physiological Research, 2023
Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X et al.
The Journal of Clinical Endocrinology and Metabolism, 2023
Parathyroid Tumors: Molecular Signatures.
Marini F et al.
International Journal of Molecular Sciences, 2021
Genetic Alteration Profiles and Clinicopathological Associations in Atypical Parathyroid Adenoma.
Mao X et al.
International Journal of Genomics, 2021
The genomic profile of parathyroid carcinoma based on whole-genome sequencing.
Hu Y et al.
International Journal of Cancer, 2020
Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas.
Cui M et al.
International Journal of Cancer, 2019
Whole-Exome Sequencing Identifies Novel Recurrent Somatic Mutations in Sporadic Parathyroid Adenomas.
Wei Z et al.
Endocrinology, 2018
Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.
Cardoso L et al.
Human Mutation, 2017
Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome.
Sun W et al.
Scientific Reports, 2017
Update on parathyroid carcinoma.
Cetani F et al.
Journal of Endocrinological Investigation, 2016
[CDC73 gene mutation and parafibromin expression status of parathyroid carcinoma in Chinese].
Kong J et al.
Zhonghua Yi Xue Za Zhi, 2013
Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
Wang O et al.
Plos One, 2012
Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses.
Cavaco BM et al.
Endocrine Pathology, 2011
[Clinical and molecular genetic analyses for a sporadic parathyroid carcinoma].
Wang CY et al.
Zhonghua Yi Xue Za Zhi, 2010
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
Hahn MA et al.
Endocrine-related Cancer, 2010
Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.
Newey PJ et al.
Human Mutation, 2010
The effect of disease-associated HRPT2 mutations on splicing.
Hahn MA et al.
The Journal of Endocrinology, 2009
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM et al.
The Journal of Clinical Endocrinology and Metabolism, 2009
HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
Cetani F et al.
Expert Review of Endocrinology & Metabolism, 2008
Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes.
Marsh DJ et al.
Expert Opinion on Medical Diagnostics, 2007
Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.
Cetani F et al.
Endocrine-related Cancer, 2007
Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.
Howell VM et al.
The Journal of Molecular Diagnostics : Jmd, 2006
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ et al.
The American Journal of Surgical Pathology, 2006
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
Shattuck TM et al.
The New England Journal of Medicine, 2003